CRISPR and the Future of Cardiac Disease Therapy: A New Genetic Frontier
International Journal of Molecular Sciences · 19.04.2026 · 27 (8) · 3641
DOI: 10.3390/ijms27083641 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 19.04.2026. Verfasst von Sem Sterckel und 2 weiteren Autor:innen. Beteiligte Einrichtung: Applied Stem Cell Technologies Group, Department of BioEngineering Technologies, Cardiovascular Health Technology Centre, Techmed Centre, University …. Hauptthemen laut MEDLINE: Genetic Therapy, Gene Editing, CRISPR-Cas Systems, Heart Diseases. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 111 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: ZonMw, The Dutch Organisation for knowledge and innovation in health, healthcare and well-being, Netherlands Organisation for Health Research and Development.
Abstract (Originalsprache)
CRISPR technologies are transforming cardiovascular therapy development by creating an increasingly seamless pipeline from potential target discovery to clinical translation. What began as a genome-editing tool has evolved into a versatile platform that enables researchers to precisely interrogate and modulate cardiac biology with tools such as base- and prime-editors, and CRISPR inhibition and activation. In this review, we follow the use of CRISPR across the stages of biomedical research through to bench-to-bedside application. This review begins by addressing how genome-wide and focused CRISPR screens discover developmental regulators, disease drivers, and drug-response pathways, making the first steps in identifying therapeutic targets. We then explore how CRISPR engineering creates progressively more relevant disease model systems to validate mechanisms of disease and test interventions, helping bridge the translational gaps between the lab and the clinic. Finally, we consider how CRISPR technologies are beginning to enter cardiovascular clinical trials, while highlighting the key challenges that still limit this translation. By linking the latest advances of modern CRISPR platforms to the stages of therapeutic development, this review highlights how CRISPR technology is reshaping the pipeline from molecular insight to clinical innovation in cardiac disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Applied Stem Cell Technologies Group, Department of BioEngineering Technologies, Cardiovascular Health Technology Centre, Techmed Centre, University of Twente, 7522 Enschede, The Netherlands.
ORCID-Profile: Sem Sterckel, Imelda Lizeth Chávez Martínez, Verena Schwach
Förderung
- ZonMw, The Dutch Organisation for knowledge and innovation in health, healthcare and well-being
- Netherlands Organisation for Health Research and Development
Zitieren
APA
Sterckel, S., Chávez Martínez, I. L., & Schwach, V. (2026). CRISPR and the Future of Cardiac Disease Therapy: A New Genetic Frontier. International Journal of Molecular Sciences, 27(8), 3641. https://doi.org/10.3390/ijms27083641
Vancouver
Sterckel S, Chávez Martínez IL, Schwach V. CRISPR and the Future of Cardiac Disease Therapy: A New Genetic Frontier. International Journal of Molecular Sciences. 2026;27(8):3641. doi:10.3390/ijms27083641
BibTeX
@article{Sterckel2026,
author = {Sterckel, Sem and Chávez Martínez, Imelda Lizeth and Schwach, Verena},
title = {CRISPR and the Future of Cardiac Disease Therapy: A New Genetic Frontier},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {8},
pages = {3641},
doi = {10.3390/ijms27083641}
}
EUVIMED